Saturday 28 April 2012
Spinal Muscular Atrophy: Avery's Bucket List Blog Raises Awareness Of The ...
TUCSON, Ariz., April 25, 2012 /PRNewswire-USNewswire/ — Repligen Corp., in Waltham, Mass., announced today that its experimental drug RG3039, designed to treat spinal muscular atrophy (SMA), was safe and well-tolerated in a phase 1TUCSON, Ariz., April 25, 2012 /PRNewswire-USNewswire/ — Repligen Corp., in Waltham, Mass., announced today that its experimental drug RG3039, designed to treat spinal muscular atrophy (SMA), was safe and well-tolerated in a phase 1Repligen licensed RG3039 in 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment